Close Menu

Biocartis

Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.

The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.

The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.

The firm said it raised €80 million to fund an expansion of, and new applications for, the Idylla test menu.

The tests were developed as part of a partnership with Merck KGaA, one of the manufacturers of the anti-EGFR therapy Erbitux.

Genomic Health will gain exclusive worldwide rights to develop and sell an IVD version of its Oncotype DX breast cancer test on Biocartis' Idylla platform.

The firm reported an 88 percent increase in product sales, but this was offset by a 79 percent drop in collaboration revenues.

The panel, developed by collaborator Janssen, is expected to improve detection of influenza and respiratory syncytial virus.

The first assay to be developed under the new five-year strategic partnership is a solid biopsy breast cancer assay designed to guide drug selection.

The lung cancer test, which can detect 51 EGFR mutations, is the fifth assay for cancer that the Belgian molecular diagnostics firm has CE marked.

Pages